LH
Light Horse Therapeutics employs a function-first approach utilizing proprietary precision gene editing and target-agnostic functional screens to discover novel therapeutic targets. This platform identifies cryptic, chemically accessible functional domains within biologic targets that drive disabling diseases. The company develops small molecule drugs to disrupt these root causes, initially focusing on challenging oncology targets.
Updated 2 months ago
Funding
$62M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Light Horse Therapeutics employs a function-first approach utilizing proprietary precision gene editing and target-agnostic functional screens to discover novel therapeutic targets. This platform identifies cryptic, chemically accessible functional domains within biologic targets that drive disabling diseases. The company develops small molecule drugs to disrupt these root causes, initially focusing on challenging oncology targets.